Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100958 · ClinicalTrials.gov registry record · Phase 1
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by University of Kansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00100958 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by University of Kansas. The trial reports 1 study location across 1 state.
The verdict
NCT00100958, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by University of Kansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of indole-3-carbinol may prevent cancer. PURPOSE: This randomized phase I trial is studying the side effects and best dose of indole-3-carbinol and to see how well it works compared to placebo in preventing cancer in healthy participants.
Conditions Studied
Interventions
- DRUG indole-3-carbinol
Study Locations (1)
Kansas
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100958
The ClinicalTrials.gov registry entry for NCT00100958 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Kansas, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention - of which indole-3-carbinol is the first listed.
NCT00100958 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT00100958 about?
NCT00100958 is a clinical study titled "Indole-3-Carbinol in Preventing Cancer in Healthy Participants". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of indole-3-carbinol may prevent cancer. PURPOSE: This randomized phase I trial is studying the side effects and best dose of indole-3-carbinol and to see how well it works compared ...
What is the current status of trial NCT00100958?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-11.
What conditions does trial NCT00100958 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00100958?
The interventions under investigation include: indole-3-carbinol (DRUG).
Who is sponsoring clinical trial NCT00100958?
This trial is sponsored by University of Kansas, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00100958 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.